Save information for later
Sign Up

Learn About Gangliosidosis

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Gangliosidosis Local Doctors?
Elite in Gangliosidosis
Medical Genetics
Elite in Gangliosidosis
Medical Genetics
111 Michigan Ave Nw, 
Washington, DC 
Languages Spoken:
English

Cynthia Tifft is a Medical Genetics provider in Washington, Washington, D.c.. Dr. Tifft is rated as an Elite provider by MediFind in the treatment of Gangliosidosis. Her top areas of expertise are Sandhoff Disease, Gangliosidosis, GM1 Gangliosidosis, and Tay-Sachs Disease.

Elite in Gangliosidosis
Elite in Gangliosidosis

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
Languages Spoken:
English
Accepting New Patients

Florian Eichler is a Neurologist in Boston, Massachusetts. Dr. Eichler is rated as an Elite provider by MediFind in the treatment of Gangliosidosis. His top areas of expertise are Adrenoleukodystrophy (ALD), CACH Syndrome, Tay-Sachs Disease, Gangliosidosis, and Gastrostomy. Dr. Eichler is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Gangliosidosis
Elite in Gangliosidosis
Kingston, ON, CA 

Jagdeep Walia practices in Kingston, Canada. Mr. Walia is rated as an Elite expert by MediFind in the treatment of Gangliosidosis. His top areas of expertise are Sandhoff Disease, Tay-Sachs Disease, Gangliosidosis, and Medium-Chain Acyl-CoA Dehydrogenase Deficiency.

What are the latest Gangliosidosis Clinical Trials?
18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Summary: An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Background: GM1 gangliosidosis is a disorder that destroys nerve cells. It is fatal. There is no treatment. People with GM1 are deficient in a certain enzyme. A gene therapy may help the body make this enzyme. This could improve GM1 symptoms.